Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices

Poon, Terence Chuen Wai

doi:10.1586/14789450.4.1.51

Cited by 141 publications

(98 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[15][16][17][18] At the same time, great concerns have also been raised regarding its reproducibility and other instrumental and technical limitations. 19,20 In the present study, we sought to determine whether serum protein expression profiling with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry platform could be used to search for potential disease-and therapy-associated markers for MDS. We analyzed serum samples from patients with del(5q) MDS before and after treatment, and those from control individuals using IMAC30-Cu 2 þ and Q10 arrays.…”

Section: Discussionmentioning

confidence: 99%

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)

Chen

Bowen²,

Giagounidis

et al. 2010

Leukemia

View full text Add to dashboard Cite

Using ProteinChip array technology, which is based on the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed proteomic analyses on sera from myelodysplastic syndromes (MDSs) patients with an interstitial deletion of the long arm of chromosome 5 (del(5q)) and those from control individuals. One analysis with 80 samples from 29 patients and 51 control subjects resulted in the detection of 61 peak differences. Another analysis with 36 paired-samples from 18 patients collected before and after the treatment with lenalidomide (Revlimid) identified 19 differential peak features. We also observed differential profiles between the pre-treatment samples from the responders and those from the non-responders reflected by eight peak differences. On the basis of these data we developed two classification models that could distinguish between the diseased and the control subjects or between the responders and the non-responders. Efforts were made to purify and identify a range of differential peak proteins. We conclude that inter-a trypsin inhibitor, heavy chain H4 (fragments), serum transferrin, transthyretin (variants), haemoglobin and a protein peak at m/z 2791 could be potential disease-associated markers for del(5q) MDS. Platelet factor 4 (PF-4) and a peak at m/z 8559 may serve as therapy-associated markers and be potentially useful for monitoring and predicting the response to therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)

Chen

Bowen²,

Giagounidis

et al. 2010

Leukemia

View full text Add to dashboard Cite

show abstract

“…The high-throughput nature and simplicity of its experimental procedures make SELDI-TOF MS a promising technology for future secretome analysis and biomarker discovery [47,48].…”

Section: Technologies Involved In Proteomicsmentioning

confidence: 99%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in terms of both incidence and mortality.The major reasons for the increasing number of deaths from lung cancer are late detection and lack of effective therapies. To improve our understanding of lung cancer biology, there is urgent need for blood-based, non-invasive molecular tests to assist in its detection in a cost-effective manner at an early stage when curative interventions are still possible. Recent advances in proteomic technology have provided extensive, high throughput analytical tools for identification, characterization and functional studies of proteomes. Changes in protein expression patterns in response to stimuli can serve as indicators or biomarkers of biological and pathological processes as well as physiological and pharmacological responses to drug treatment, thus aiding in early diagnosis and prognosis of disease. However, only a few biomarkers have been approved by the FDA to date for screening and diagnostic purposes. This review provides a brief overview of currently available proteomic techniques, their applications and limitations and the current state of knowledge about important serum biomarkers in lung cancer and their potential value as prognostic and diagnostic tools.

show abstract

“…Protein profiling by MS is a technology that can be easily transferred into high-throughput applications with the aid of robotised sample handling, atomised MS measurements and data analysis [50][51][52]. A general advantage of MS-based approaches is that it allows the visualisation of different isoforms of the same protein, which are otherwise difficult to distinguish by ELISA-based methods [53,54].…”

Section: Antigen Profiling By Msmentioning

confidence: 99%

Immunoproteomics: From biomarker discovery to diagnostic applications

Tjalsma

Schaeps

Swinkels

2008

Proteomics Clinical Apps

View full text Add to dashboard Cite

Circulating antibodies reflect a molecular imprint of antigens that are related to autoimmune diseases, cancer or infection. Importantly, serum antibodies are useful clinical markers as they carry diagnostic information from all around the human body. Moreover, the amplification cascade governed by the humoral immune system causes a surplus of circulating antibodies after appearance of the corresponding (low abundance) antigen. In combination with the fact that antibodies are highly stable compared to many other serum proteins, they seem ideal to be implemented in clinical diagnostic assays for the detection of antigen-associated diseases. This review summarises advances in immunoproteomics with respect to technologies for biomarker discovery, with special emphasis on recently developed gel-free MS-based approaches, and looks forward to potential immunoproteomic applications in diagnostic medicine.

show abstract

Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices

Cited by 141 publications

References 84 publications

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)

Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)

Serum-based protein biomarkers for detection of lung cancer

Immunoproteomics: From biomarker discovery to diagnostic applications

Contact Info

Product

Resources

About